Debiopharm, Oncodesign Services announce license agreement for use of AbYlink technology for pre-clinical services: Martigny, Switzerland Saturday, April 26, 2025, 17:00 Hrs [IST] ...

Debiopharm further describes AbYlink as a one-step method that results in stable conjugation at defined and invariable sites on the Fc domain of an antibody, with no impact on antigen-binding regions, ...

PALO ALTO, CA, UNITED STATES, April 25, 2025 /EINPresswire.com/ -- Preclinical results for lead ADC candidate BLB-101 for Claudin 6/9+ tumors supports potential best-in-class profile. Data presented ...

Clinical findings show association between nadunolimab and lower incidence and later onset of CIPNPreclinical data show prevention of both chemotherapy- and antibody-drug conjugate- (ADC) ...

Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical modelsAnti-IL1RAP ADC targets IL1RAP, which is overexpressed in many tumors and their tumor microenvironm ...

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission ...

Zai Lab Limited will present new data from studies evaluating two of its internally developed, next-generation, investigational oncology therapies that it has global rights to, ZL-6201, a novel ...

Elevation Oncology, Inc. , an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet ...

CatalYm today announced the presentation of the first preclinical data demonstrating that the company’s clinical-stage ...

Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...

Phase 1 trial of TGW101 in advanced solid tumors is enrolling to assess safety and pharmacokinetics and define the maximum ...

AbbVie (ABBV) stock gains as the company lifts 2025 earnings outlook after strong Q1 results, driven by its newer immunology ...